EPHA7 and colorectal cancer: This could partially explain why EPHA7-MUT colorectal cancer was the only one that presented with worse OS in the validation cohort, because the harmful prognostic impact of EPHA7-MUT outweighed its ICI treatment benefits in colorectal cancer.